

PROVINCIAL FUNDING SUMMARY

Pembrolizumab (Keytruda) for Squamous NSCLC (pCODR 10176)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: January 20, 2020

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

| PROVINCE | FUNDING STATUS | FUNDING DATE | FUNDING CRITERIA |
|----------|----------------|--------------|---|
| BC | Funded | Jun 1, 2020 | <p>Previously untreated advanced non-small cell lung cancer</p> <ul style="list-style-type: none"> • Restricted to disease of squamous cell histology • ECOG 0-2 • Adequate hepatic and renal function • Asymptomatic/stable brain metastases (if applicable) |
| AB | Funded | Sep 15, 2020 | <p>In combination with carboplatin and paclitaxel for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) who have no prior systemic chemotherapy treatment for metastatic NSCLC. Patients previously treated with durvalumab in the adjuvant setting who have relapsed after the completion of adjuvant therapy must have had at least a six month interval off durvalumab with no disease recurrence while on durvalumab. Treatment should continue until confirmed disease progression or unacceptable toxicity to a maximum of two years, whichever comes first. (note: if the clinical situation dictates it would be reasonable to use other platinum based therapies (eg intolerant to taxanes).</p> |
| SK | Funded | May 1, 2020 | <p>In combination with platinum-based chemotherapy for the treatment of metastatic squamous non-small cell lung cancer (SQ-NSCLC), in adults with no prior systemic chemotherapy treatment for metastatic NSCLC and who have good performance status •Treatment may continue until confirmed disease progression or unacceptable toxicity, or after completing a maximum of 2 years of Pembrolizumab therapy, whichever comes first First-Line SQ-NSCLC Funding Notes: -Only patients who are candidates for platinum-based chemotherapy (preferably Paclitaxel-Carboplatin) for SQ-NSCLC are eligible</p> |

| PROVINCE | FUNDING STATUS | FUNDING DATE | FUNDING CRITERIA |
|----------|----------------|--------------|--|
| | | | for first line treatment in combination with Pembrolizumab -Patients who received Durvalumab for stage III NSCLC are eligible for Pembrolizumab in the metastatic setting only if there has been at least a 6 month progression-free interval between completion of Durvalumab and confirmation of disease progression -If Pembrolizumab is stopped in the setting of maximum response/stable disease or after completion of 2 years of therapy, it may be re-started at the time of disease progression for an additional 1 year of therapy -Patients who received Pembrolizumab as part of first-line therapy and experienced disease progression on treatment are not eligible for any further immunotherapy options as a subsequent line of therapy |
| MB | Funded | Apr 30, 2020 | In combination with platinum-doublet chemotherapy for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC), in adults with no prior systemic chemotherapy treatment for metastatic NSCLC. Eligible patients should have good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity to a maximum of two years, whichever comes first. Retreatment: Patients can receive up to an additional 12 months of pembrolizumab if they experience disease progression after previously stopping their initial treatment with pembrolizumab after receiving 35 administrations (cycles). |
| ON | Funded | Jun 10, 2020 | Pembrolizumab is used in combination with carboplatin and paclitaxel for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not had prior systemic chemotherapy for metastatic NSCLC. Treatment should be for patients with good performance status. Pembrolizumab should be given in combination with carboplatin and paclitaxel for the first 4-6 cycles, followed by pembrolizumab as a single agent for the maintenance phase. Treatment should be continued until disease progression or unacceptable toxicity up to a maximum of 2 years' worth of treatment, whichever comes first. Patients who complete 2 years' worth of treatment without disease progression may receive up to an additional 1 year's worth of treatment at the point of confirmed disease progression if the treating physician deems the patient eligible for retreatment. |

| PROVINCE | FUNDING STATUS | FUNDING DATE | FUNDING CRITERIA |
|----------|--------------------------------|--------------|--|
| NS | Funded | May 1, 2020 | In combination with carboplatin and paclitaxel chemotherapy for the treatment of metastatic squamous non-small cell lung cancer (NSCLC), in patients with no prior systemic chemotherapy treatment for metastatic NSCLC. Patients should have a good performance status. Treatment should continue until confirmed disease progression or unacceptable toxicity, or to a maximum of two years (35 cycles), whichever comes first. Patients who complete 2 years of therapy (35 cycles), or less than 2 years in the setting of maximum response, may receive up to an additional 12 months (17 cycles) at the point of confirmed disease progression if the treating physician deems the patient eligible for treatment. Funding is limited to one line of PD-1 inhibitor therapy for patients with advanced or metastatic non-small cell lung cancer (ie: one of Pembrolizumab 1st line, Pembrolizumab 2nd line or beyond, or Nivolumab). Patients who have been treated with curative intent durvalumab will be eligible for treatment with combination pembrolizumab with carboplatin and paclitaxel chemotherapy in the metastatic setting, provided that there has been a 6 month interval between the completion of durvalumab treatment and metastatic disease. |
| NB | Funded | Jul 16, 2020 | In combination with platinum-doublet chemotherapy for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults with no prior systemic chemotherapy treatment for metastatic NSCLC. Patients must have a good performance status. Treatment should be discontinued upon confirmed disease progression, unacceptable toxicity or after completing two years of therapy, whichever occurs first. |
| NL | Funded | Jun 1, 2020 | <ul style="list-style-type: none"> As first-line therapy in combination with platinum and taxane doublet chemotherapy in adult patients with no prior systemic chemotherapy treatment for metastatic squamous NSCLC Patients must have good performance status Treatment should continue until disease progression or unacceptable toxicity, up to a maximum of 2 years (35 cycles) |
| PEI | Under provincial consideration | | |

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has

recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.